# A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

> clinical trial · VERIFIED · 2026-07-09

Status: RECRUITING · Sponsor: BeOne Medicines · Condition: CLL

- Company: BeOne Medicines
- Sector: CLL
- Primary source: https://clinicaltrials.gov/study/NCT06846671

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.